441 related articles for article (PubMed ID: 30457349)
21. Efficacy of Hippotherapy Versus Pharmacotherapy in Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.
Oh Y; Joung YS; Jang B; Yoo JH; Song J; Kim J; Kim K; Kim S; Lee J; Shin HY; Kwon JY; Kim YH; Jeong B
J Altern Complement Med; 2018 May; 24(5):463-471. PubMed ID: 29641212
[TBL] [Abstract][Full Text] [Related]
22. Prescribing patterns for attention deficit hyperactivity disorder among children and adolescents in Taiwan from 2004 to 2017.
Liao HC; Lin FJ; Hsu CN; Gau SS; Wang CC
J Formos Med Assoc; 2023 Jun; 122(6):514-517. PubMed ID: 36931958
[TBL] [Abstract][Full Text] [Related]
23. A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.
Arnold LE; Ober N; Aman MG; Handen B; Smith T; Pan X; Hyman SL; Hollway J; Lecavalier L; Page K; Rice R
J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):322-330. PubMed ID: 29694241
[TBL] [Abstract][Full Text] [Related]
24. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
Gibson AP; Bettinger TL; Patel NC; Crismon ML
Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
[TBL] [Abstract][Full Text] [Related]
25. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
[TBL] [Abstract][Full Text] [Related]
26. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
[TBL] [Abstract][Full Text] [Related]
27. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
28. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of attention-deficit/hyperactivity disorder in clinical practice. A retrospective study].
López-López A; Poch-Olivé ML; López-Pisón J; Cardo-Jalón E;
Medicina (B Aires); 2019; 79(Suppl 1):68-71. PubMed ID: 30776283
[TBL] [Abstract][Full Text] [Related]
30. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
[TBL] [Abstract][Full Text] [Related]
31. Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: a (1)H magnetic resonance spectroscopy study.
Husarova V; Bittsansky M; Ondrejka I; Dobrota D
Psychiatry Res; 2014 Apr; 222(1-2):75-83. PubMed ID: 24679996
[TBL] [Abstract][Full Text] [Related]
32. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
Ozbaran B; Kose S; Yuzuguldu O; Atar B; Aydin C
World J Biol Psychiatry; 2015; 16(8):619-24. PubMed ID: 26223958
[TBL] [Abstract][Full Text] [Related]
33. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Cortese S; Adamo N; Del Giovane C; Mohr-Jensen C; Hayes AJ; Carucci S; Atkinson LZ; Tessari L; Banaschewski T; Coghill D; Hollis C; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A
Lancet Psychiatry; 2018 Sep; 5(9):727-738. PubMed ID: 30097390
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.
Kemner JE; Starr HL; Ciccone PE; Hooper-Wood CG; Crockett RS
Adv Ther; 2005; 22(5):498-512. PubMed ID: 16418159
[TBL] [Abstract][Full Text] [Related]
36. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
[TBL] [Abstract][Full Text] [Related]
37. Prevalence rates of youths diagnosed with and medicated for ADHD in a nationwide survey in Taiwan from 2000 to 2011.
Wang LJ; Lee SY; Yuan SS; Yang CJ; Yang KC; Huang TS; Chou WJ; Chou MC; Lee MJ; Lee TL; Shyu YC
Epidemiol Psychiatr Sci; 2017 Dec; 26(6):624-634. PubMed ID: 27435692
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis.
Hanwella R; Senanayake M; de Silva V
BMC Psychiatry; 2011 Nov; 11():176. PubMed ID: 22074258
[TBL] [Abstract][Full Text] [Related]
39. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.
Bushe CJ; Savill NC
J Psychopharmacol; 2014 Mar; 28(3):204-11. PubMed ID: 23438503
[TBL] [Abstract][Full Text] [Related]
40. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]